News on mass spectrometry technology and applications in genetics, genomics, and molecular diagnostics.
The instrument is not as much of a turnkey solution as recent releases from Sciex and Thermo Fisher but marks a step in that direction for Agilent.
While Sera's previous validation work focused on the 37 and 35 week time points, the 32 week mark is perhaps most crucial in terms of patient outcomes.
The company said that it will use the funds to build out its CLIA facility and continue developing its blood-based Alzheimer's disease test for the clinic.
The company has identified progesterone metabolites linked to preterm birth and is looking to develop them for predicting risk of delivery prior to 32 weeks.
The firm is planning a prospective trial for the test after results in a small retrospective study showed good performance in identifying cancers and precancers.
